Cohesive Technologies Inc. Announces Development, Sales, and Support Agreement with Applied Biosystems FRANKLIN, Mass., Feb. 12 /PRNewswire/ -- Cohesive Technologies Inc. (http://www.cohesivetech.com/), developers of TurboFlow(R), a technology for high throughput liquid chromatography systems, announced today that it has entered into a development, sales, and support agreement with Applied Biosystems Group , an Applera Corporation business. The agreement covers LC/MS/MS systems jointly developed by Applied Biosystems and MDS Inc. , through its Applied Biosystems/MDS Sciex instrument partnership, a supplier of mass spectrometers and other analytical instrumentation. Because the companies have complementary products and technologies, this agreement allows Cohesive and Applied Biosystems to jointly provide their customers with a complete, seamless, integrated, high throughput system for bioanalysis in drug development. Cohesive's patented chromatography systems, offering increased productivity and throughput, sample prep elimination, and high sensitivity, will be integrated with the Applied Biosystems/MDS Sciex product line of highly sensitive mass spectrometers. Under this agreement, Cohesive Technologies and Applied Biosystems agree to broaden their collaboration on joint system development, including modifying software to provide seamless management and single point control of all system functions, and developing new applications for the combined technologies. "Our industry leading technology and recently expanded strategic collaboration with Applied Biosystems enables us to build on our combined strength in bioanalysis, and provides an opportunity to integrate liquid chromatography/mass spectrometry systems closer than ever before for our customers," said Peter H. Glick, President and CEO of Cohesive Technologies. "We look forward to continuing our strong collaboration with Applied Biosystems to maximize the significant opportunities that our companies' technologies present." Cohesive Technologies develops, manufactures, and markets novel liquid chromatography systems and chemistries for the pharmaceutical and biotechnology marketplace. Cohesive's high throughput liquid chromatography systems have been shown to dramatically increase speed and reduce costs of bioanalytical testing for drug discovery and development. Researchers at dozens of major pharmaceutical and biotechnology companies have published results indicating up to a four-fold increase in sample throughput usingCohesive's multiplexing and patented TurboFlow(R) technologies. The Company has over 300 systems installed worldwide. DATASOURCE: Cohesive Technologies Inc. CONTACT: Jeff Zonderman, Director of Sales of Cohesive Technologies Inc., +1-508-520-5533

Copyright